BioXcel Therapeutics, Inc. (BTAI) is a NasdaqCM-listed biopharmaceutical company that has seen considerable institutional activity and notable price movements.1
Here's a snapshot of key data points for BTAI:
- Institutional Ownership: Fintel data indicates that 38 institutional owners hold a total of 384,437 shares. This represents a significant quarter-over-quarter increase of 153.33% in the number of institutions and an 829.33% increase in the total shares held.1 Notable institutional holders include Murchison Ltd., UBS Group AG, Goldman Sachs Group Inc, BlackRock, Inc., and Vanguard Group Inc.1 This surge in institutional interest suggests increased accumulation by funds, as reflected by Fintel's Fund Sentiment Score, which identifies companies with high levels of institutional buying.1
- Short Interest: The short interest in BTAI stands at 352,193 shares, with a Short Interest % Float of 6.39%. The Days to Cover is relatively low at 0.01.2 Furthermore, off-exchange short volume is substantial, with 10,797,416 shares and an Off-Exchange Short Volume Ratio of 56.62%.2 This indicates a significant portion of short selling activity occurring outside traditional exchanges.
- Analyst Sentiment: The average one-year price target for BTAI is $16.83, with a wide range from $1.01 to $69.30.3 This broad range suggests varied analyst opinions on the company's future valuation.
- Recent Performance: The stock has experienced a substantial decline, with its share price as of August 6, 2025, at $3.31, marking a 77.30% decrease from $14.58 on August 7, 2024.1
- Piotroski F-Score: BTAI currently holds a Piotroski F-Score of 3.00 out of 9, which is a quantitative measure of financial health.3
The confluence of increasing institutional ownership and significant short interest could indicate a divergence in market sentiment or potential for volatility. Investors might find it valuable to further explore the drivers behind the institutional accumulation amidst the recent price depreciation.
